ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review and meta-analysis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCirculating cytokines can influence tumor progression and immune evasion, serving as non-invasive biomarkers in digestive system (DS) cancers. This study evaluates the prognostic significance of biofluid cytokines in DS cancers.
methodsComprehensive literature search in various databases identified studies reporting the prognostic importance of serum or plasma cytokines based on multivariate data, focusing on overall survival (OS) and disease/relapse/progression-free/cancer-specific-survivals (DFS/RFS/PFS/CSS). Quality assessment was done using the Newcastle-Ottawa scale. Heterogeneity was evaluated through Chi-square-based Q and I2 analyses. Publication bias was assessed via funnel plots, Egger's, Begg's, and trim-and-fill methods, alongside subgroup and sensitivity analyses.
resultsA total of 42 articles evaluating 7 blood cytokines in DS cancers were included, with IL-6 and the CXCL family being the most studied. Elevated IL-6 levels were significantly associated with poor survival outcomes in esophageal, hepatocellular, biliary tract, pancreatic, and colorectal cancers for both OS and DFS/RFS/PFS/CSS. High CXCL levels correlated with worse prognosis in colorectal (OS: HR = 2.019) and hepatocellular (OS: HR = 5.569, DFS/RFS/PFS/CSS: HR = 1.610) cancer patients. Higher CCL levels predicted poor OS (HR = 1.912) in colorectal cancer. Circulating IL-10, IL-1β, and TNF-α showed no significant correlation with survival outcomes in DS. Subgroup analyses revealed varying prognostic significances of each cytokine in different DS malignancies. Publication bias was minimal except for IL-6 in pancreatic carcinoma, affirming the robustness of most outcomes.
conclusionElevated circulating IL-6, CXCL, and CCL families may predict poor prognosis in certain DS, highlighting their potential as prognostic markers. Further studies are needed to translate these findings into clinical practice. PROSPERO REGISTRATION NUMBER: CRD42022316733.
Indexed as
Identifiers
42844510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.